Metastasectomy has long been considered a valid treatment option for patients with oligometastatic renal cell carcinoma (oligo-mRCC). However, the literature on complications in this setting is scarce. Our objective was to describe in-hospital complications after metastasectomy in a contemporary cohort of patients with mRCC. Using the National Inpatient Sample database (2000-2011), 45 279 mRCC patients were identified. Of those, 1102 underwent metastasectomies. The metastatic sites were the lungs, bone, liver, lymph nodes, adrenal glands, and brain in, respectively, 52%, 29%, 19%, 14%, 11%, and 3.4% of patients. The overall complication rate was 45.7%. Major complications (Clavien III-V) constituted 27.5%. Resections of hepatic lesions were significantly associated with higher odds of overall complications compared with any other site (odds ratio 2.59, 95% confidence interval 1.84-3.62, p<0.001). While metastasectomy remains a potential treatment option in RCC with oligometastatic disease, the associated complication rates are non-negligible; therefore, careful patient selection is warranted.
We studied outcomes of patients with metastatic kidney cancer treated with metastasectomy. While metastasectomy is a treatment option for metastatic renal cell carcinoma, complications are not insignificant and our results may guide preoperative counseling.
European urology. 2017 Mar 27 [Epub ahead of print]
Christian P Meyer, Maxine Sun, Jose A Karam, Jeffrey J Leow, Guillermo de Velasco, Sumanta K Pal, Steven L Chang, Quoc-Dien Trinh, Toni K Choueiri
Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Center for Surgery and Public Health, Division of Urologic Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA., Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain., Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, USA., Department of Medical Oncology, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Electronic address: .